Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Panic Disorder

PORTLAND, Ore. (PRWEB) June 23, 2020 Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative CNS therapies, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase…

Source link

Related posts

Polarized light sensitivity in Pieris rapae is dependent on both color and intensity [RESEARCH ARTICLE]


Macrophages as Both Friends and Foes in Age-Related Diseases


Heat Shock Proteins Support Refolding and Shredding of Misfolded Proteins


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World